Média

AMAG PHARMACEUTICALS ET NORGINE B.V. CONCLUENT UN ACCORD DE LICENCE EXCLUSIVE POUR COMMERCIALISER CIRAPARANTAG EN EUROPE, AUSTRALIE ET NOUVELLE- ZÉLANDE
08 Septembre 2020

NORGINE A FAIT L’ACQUISITION DU LABORATOIRE AZANTA, RENFORÇANT SA POSITION DE LABORATOIRE PHARMACEUTIQUE LEADER EUROPEEN
19 Mai 2020

Voir plus

Infographic

Partnering is core to our business. It is an important element in Norgine’s success and is fundamental to the company’s continued growth and success.

Our approach to partnering is flexible which helps to meet the challenges faced by the pharmaceutical sector. We partner in many different ways. Norgine finds and works with partners with complementary skills and a shared vision for improving healthcare.

Listen to Peter Stein talking on BioCentury TV about the challenges for U.S. biotech and device companies seeking to access the European markets

 

Partnering is core to our business

 

In-licensing:
Norgine wants to access new products and technology that fit with our strategic objectives and ensures that we have a pipeline of new products to sell.

×

Alliance management:
Our Corporate and Business Development department is a global team of business development and alliance management experts who manage the selection and review of in and out licensing opportunities, lead the deal process and actively manage all of our strategic alliances, to build strong relationships that are mutually beneficial to both partners and Norgine.

×

Out-licensing:
We want to make Norgine products available to patients in territories where Norgine does not have its own sales force by utilising the local knowledge and expertise of our partners.

×

Novel partnering:
Norgine partners in many different ways. We offer flexible approaches ranging from standard licensing agreements to more complex Joint Ventures structures. All our partners can access Norgine’s pan-European infrastructure as and when required.

×